PANASONIC
26.5.2020 12:50:05 CEST | Business Wire | Press release
Panasonic Center Tokyo (3-5-1 Ariake, Koto-ku, Tokyo, Japan. Referred to as "PC Tokyo"), the corporate global communications hub for Panasonic, has been conducting various communication activities as a corporate pavilion through exhibitions and offline events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005385/en/
Due to the unprecedented circumstances around the world today, people's daily lives and values have been significantly impacted. We, at Panasonic, believe a new approach blending online and offline communication activities will be an essential element for corporate pavilions now more than ever.
Based on this perspective, we have decided to host an online event called "The power to create the future", on Sunday, May 31, 2020. An event dedicated to children, who we believe have the ability to become "change makers" and bring a positive impact to society, to create a better world.
The theme of the event is "STEAM education*", a very important element required for future education as the world is rapidly changing. During the event, STEAM professionals will conduct a workshop which will give the participants an opportunity to think and understand more about STEAM in their daily lives. Olympian Katie Ledecky will also join the event to introduce the Dive Into STEM Education, Powered by Panasonic program.
Katie Ledecky's Dive Into STEM Education Powered by Panasonic is an interactive educational program created to inspire students to pursue careers in science, technology, engineering and mathematics.
The students participating in the event will be divided into different groups where they will conduct a series of interviews with our guests to learn more about STEAM, and then will make a presentation about what they have learned. At the end of the event, participants will hear from Katie, who is actively working on educational support activities for younger generations.
PC Tokyo aims to proactively support the education program of younger generations by providing fresh contents such as videos of online events available on the pavilion's website.
Message from Katie Ledecky towards the event
"I am thrilled to join Panasonic Center Tokyo to promote STEM education to a group of Japanese students on May 31st.
All are welcome to join our training workshop. Hope to see you soon."
Video: “Katie Ledecky's Dive Into STEM Education Powered by Panasonic”
https://youtu.be/31DmQXq0sTw
*STEAM education is an educational method which was proposed by adding Art to "STEM education"; a method to learn about Science, Technology, Engineering, and Mathematics comprehensively.
STEAM education was introduced in the United States to contribute to the development of younger generations to inspire them to pursue diverse career fields. This method is also attracting a lot of attention in Japan in recent years.
"The power to create the future" Event outline
Date
Saturday, May 30, 2020 at 6:00pm-7:40pm PDT / 9:00pm-10:40pm EDT
Sunday, May 31, 2020 at 10:00am-11:40am JST
Place
Live stream of the online event: https://youtu.be/aiLyPX7SmTM
Details: https://www.panasonic.com/global/corporate/center-tokyo/en.html#steam_0531
*The live stream is recorded and can be viewed afterwards.
Target
Junior and senior high school students, educators, and those who have interest in STEAM education
Cooperation
Kyodo News (junior press), EverFi (contents for the event)
*The event will be conducted in English. Admission free.
About Panasonic
Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th anniversary in 2018, operates 528 subsidiaries and 72 associated companies worldwide and reported consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. Learn more about Panasonic: https://www.panasonic.com/global .
Source: https://news.panasonic.com/global/topics/2020/78373.html
Related Links
Panasonic Center Tokyo official website
https://panasonic.com/global/center-tokyo/en/
Event Reports - Panasonic Center TOKYO
https://www.panasonic.com/global/corporate/center-tokyo/en/event_report.html#StayHome_contents
Video: Panasonic Partners With The Michael Phelps Foundation #whatmovesus
https://channel.panasonic.com/contents/28784/
Video: Team Panasonic is forward moving #whatmovesus
https://channel.panasonic.com/contents/28785/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200526005385/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom